Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - RESMED INC | d664580d8k.htm |
Exhibit 99.1
RESMED INC. ANNOUNCES RECORD FINANCIAL RESULTS FOR THE
QUARTER ENDED AND SIX MONTHS ENDED DEC. 31, 2013
SAN DIEGO, California, Jan. 23, 2014 – ResMed Inc. (NYSE: RMD) today announced record revenue and income for the quarter ended Dec. 31, 2013. Revenue for the quarter ended Dec. 31, 2013 was $384.3 million, a 2 percent increase (a 1 percent increase on a constant currency basis) over the quarter ended Dec. 31, 2012. For the quarter ended Dec. 31, 2013, net income was $86.6 million, an increase of 11 percent compared to the quarter ended Dec. 31, 2012. Diluted earnings per share for the quarter ended Dec. 31, 2013 were $0.60, an increase of 13 percent compared to the quarter ended Dec. 31, 2012.
SG&A expenses were $111.7 million for the quarter ended Dec. 31, 2013, an increase of 4 percent (a 5 percent increase on a constant currency basis) over the quarter ended Dec. 31, 2012. SG&A costs were 29.1 percent of revenue in the quarter ended Dec. 31, 2013, compared to 28.6 percent in the quarter ended Dec. 31, 2012.
R&D expenses were $29.5 million for the quarter ended Dec. 31, 2013, or 7.7 percent of revenue. R&D expenses decreased by 3 percent (a 5 percent increase on a constant currency basis) compared to the quarter ended Dec. 31, 2012. R&D expenses were favorably impacted by the depreciation of the Australian dollar against the U.S. dollar.
The company amortized acquired intangibles of $2.5 million ($1.9 million, net of tax) during the quarter ended Dec. 31, 2013. Stock-based compensation costs incurred during the quarter ended Dec. 31, 2013 of $10.7 million ($7.2 million, net of tax) consisted of expenses associated with stock options, restricted stock units, and our employee stock purchase plan.
For the six months ended Dec. 31, 2013, revenue was $742.0 million, an increase of 4 percent over the six months ended Dec. 31, 2012 (a 3 percent increase on a constant currency basis). For the six months ended Dec. 31, 2013, net income was $167.6 million, an increase of 12 percent compared to the six months ended Dec. 31, 2012. Diluted earnings per share for the six months ended Dec. 31, 2013 were $1.15 per diluted share, an increase of 13 percent compared to the six months ended Dec. 31, 2012.
In the second quarter of fiscal 2014, revenue outside the Americas was $177.7 million, an increase of 8 percent over the prior year’s quarter. In constant currency terms, revenue outside the Americas increased by 5 percent. Revenue in the Americas decreased by 2 percent compared to the prior year’s quarter, to $206.6 million. Operating profit for the December quarter grew to $105.0 million, cash flow from operations was $84.2 million, while gross margin expanded to 64.7 percent, all demonstrating robust operating performance. During the quarter, the company also repurchased 1.5 million shares at a cost of $74.0 million as part of its ongoing capital management program.
Mick Farrell, ResMed’s chief executive officer, commented, “‘While we are disappointed with the U.S. numbers, the two key issues, as we have previously noted, are market restructuring due to competitive bidding and increased competitor activity. Having said that, competitive bidding’s impact on volume in the U.S. market is beginning to moderate, and we are partnering with our U.S. customers to position for the growth that we see ahead. It’s important to note that we have a rich pipeline of products scheduled for introduction, and we remain optimistic about future growth in the U.S. market.
Highlighting an example of the company’s new product pipeline, Farrell said, “Earlier this month in the U.S., we released our new AirFit™ P10 nasal pillows system, which is an ultra-light, ultra-quiet mask that has only three parts, including a new soft and stable QuickFit™ headgear and a new vent technology called QuietAir™. The AirFit P10 is 50 percent quieter and 50 percent lighter than its predecessor, diffusing air with minimal disturbance to patients or their bed partners. In short, this is an exceptional mask, patient reviews have been strongly positive, and there are two more new masks behind it, scheduled to launch this fiscal year.
“During the second quarter, the Health Surveillance Agency approved our Stellar™ ventilator for sale in Brazil. And we are on track to launch our next generation respiratory care ventilator platform in Europe in fiscal year 2014, with other markets to follow. We expect these launches and others from our pipeline to drive further growth in our global markets,” he said.
“During this fiscal quarter, we benefitted from our broad global diversification with solid growth from our European teams and in our emerging market countries. Our German homecare and dealer businesses performed well in the quarter, and sales were strong in the U.K., Switzerland, and in European countries where we do not have direct subsidiaries. We are pleased with our global operational performance, which allowed us to expand gross margins, and grow earnings at double-digit rates this quarter,” Farrell continued.
“Opportunities for growth remain in sleep, respiratory care, and cardiorespiratory markets in all geographies. We continue to focus on improving quality of life for patients who suffer from sleep-disordered breathing and respiratory insufficiency, including chronic obstructive pulmonary disease. Our team has the mission of preventing disease progression, improving outcomes, and reducing the cost of managing some of the most costly chronic diseases in the global healthcare system, including cardiovascular disease.”
The ResMed board of directors has today declared a quarterly dividend of $0.25 per share, which will have a record date of Feb. 19, 2014, and be payable on March 19, 2014. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange (NYSE). Holders of Chess Depositary Instruments (CDIs) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. Because the two exchanges have different settlement and transfer procedures, the ex-dividend periods before the record date will be different for common stock and for CDIs. The ex-dividend date will be Feb. 13, 2014 for CDI holders and Feb. 15, 2014 for common stock holders. As a result of these differences, ResMed has requested a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from Feb. 13, 2014 through Feb. 19, 2014, inclusive.
About ResMed
ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.
ResMed will host a conference call at 1:30 p.m. U.S. Pacific Time today to discuss these quarterly results. Individuals wishing to access the conference call may do so via ResMed’s website at www.resmed.com or by dialing 847-585-4405 (domestic) or +1 847-585-4405 (international) and entering conference passcode no. 36303553. Please allow extra time prior to the call to visit the website and download the streaming media player (Windows Media Player) required to listen to the internet broadcast. The online archive of the broadcast will be available approximately 30 minutes after the live call and will be available for two weeks. A telephone replay of the conference call is available by dialing 630-652-3042 (domestic) and +1 630-652-3042 (international) and entering conference I.D. No. 36303553.
For Investors: Further information can be obtained by contacting David Pendarvis at ResMed Inc., San Diego, at (858) 836-5983; Brett Sandercock at ResMed Limited, Sydney, at (+612) 8884-2090; or by visiting the company’s multilingual website at www.resmed.com.
For News Media: Contact Gretchen Griswold, director of Global Corporate Communications at (858) 836-6789.
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the company’s future revenue, earnings or expenses, new product development and new markets for the company’s products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the company’s Annual Report on Form 10-K for its most recent fiscal year and in other reports the company files with the U.S. Securities & Exchange Commission. Those reports are available on the company’s website.
- More -
RESMED INC AND SUBSIDIARIES
Condensed Consolidated Statements of Income (Unaudited)
(In US$ thousands, except per share data)
| Three Months Ended Dec. 31, |
Six Months Ended Dec. 31, |
|||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||
| Net revenue |
$ | 384,341 | $ | 376,537 | $ | 742,003 | $ | 716,269 | ||||||||
| Cost of sales |
135,582 | 143,825 | 265,263 | 274,909 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Gross profit |
248,759 | 232,712 | 476,740 | 441,360 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Operating expenses: |
||||||||||||||||
| Selling, general and administrative |
111,748 | 107,815 | 213,071 | 206,118 | ||||||||||||
| Research and development |
29,537 | 30,326 | 56,900 | 57,546 | ||||||||||||
| Amortization of acquired intangible assets |
2,454 | 2,501 | 4,866 | 5,138 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
143,739 | 140,642 | 274,837 | 268,802 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Income from operations |
105,020 | 92,070 | 201,903 | 172,558 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Other income (expenses), net: |
||||||||||||||||
| Interest income (expense), net |
6,752 | 8,498 | 13,166 | 16,970 | ||||||||||||
| Other, net |
(2,311 | ) | (2,168 | ) | (3,539 | ) | (227 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total other income (expenses), net |
4,441 | 6,330 | 9,627 | 16,743 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Income before income taxes |
109,461 | 98,400 | 211,530 | 189,301 | ||||||||||||
| Income taxes |
22,825 | 20,458 | 43,964 | 40,094 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income |
$ | 86,636 | $ | 77,942 | $ | 167,566 | $ | 149,207 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Basic earnings per share |
$ | 0.61 | $ | 0.54 | $ | 1.18 | $ | 1.04 | ||||||||
| Diluted earnings per share |
$ | 0.60 | $ | 0.53 | $ | 1.15 | $ | 1.02 | ||||||||
| Basic shares outstanding |
142,202 | 143,214 | 142,103 | 142,931 | ||||||||||||
| Diluted shares outstanding |
145,335 | 146,689 | 145,412 | 146,382 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
- More -
RESMED INC AND SUBSIDIARIES
Condensed Consolidated Balance Sheets (Unaudited - In US$ thousands)
| Dec. 31, 2013 | June 30, 2013 | |||||||
| ASSETS |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 972,675 | $ | 876,048 | ||||
| Accounts receivable, net |
301,627 | 318,349 | ||||||
| Inventories |
178,077 | 145,847 | ||||||
| Prepayments, deferred income taxes and other current assets |
111,753 | 108,605 | ||||||
|
|
|
|
|
|||||
| Total current assets |
1,564,132 | 1,448,849 | ||||||
|
|
|
|
|
|||||
| Property, plant and equipment, net |
414,344 | 411,433 | ||||||
| Goodwill |
290,045 | 274,829 | ||||||
| Other intangibles |
46,702 | 49,639 | ||||||
| Deferred income taxes and other non-current assets |
30,365 | 25,971 | ||||||
|
|
|
|
|
|||||
| Total non-current assets |
781,456 | 761,872 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 2,345,588 | $ | 2,210,721 | ||||
|
|
|
|
|
|||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
56,235 | 60,688 | ||||||
| Accrued expenses |
141,946 | 137,674 | ||||||
| Deferred revenue |
42,648 | 44,953 | ||||||
| Income taxes payable |
1,223 | 30,090 | ||||||
| Deferred income taxes |
741 | 627 | ||||||
| Current portion of long-term debt |
18 | 300,017 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
242,811 | 574,049 | ||||||
|
|
|
|
|
|||||
| Non-current liabilities: |
||||||||
| Deferred income taxes |
10,274 | 9,895 | ||||||
| Deferred revenue |
14,193 | 11,928 | ||||||
| Income taxes payable |
3,564 | 3,564 | ||||||
| Non-current portion of long-term debt |
435,794 | 769 | ||||||
|
|
|
|
|
|||||
| Total non-current liabilities |
463,825 | 26,156 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
706,636 | 600,205 | ||||||
|
|
|
|
|
|||||
| STOCKHOLDERS’ EQUITY: |
||||||||
| Common stock |
566 | 568 | ||||||
| Additional paid-in capital |
1,065,326 | 1,025,064 | ||||||
| Retained earnings |
1,673,083 | 1,576,641 | ||||||
| Treasury stock |
(1,178,946 | ) | (1,083,845 | ) | ||||
| Accumulated other comprehensive income |
78,923 | 92,088 | ||||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
1,638,952 | 1,610,516 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 2,345,588 | $ | 2,210,721 | ||||
|
|
|
|
|
|||||
- End -